Immunotherapy for Merkel cell carcinoma -- novel research highlights quality of life benefits

December 11, 2017

11th December 2017

Future Science Group (FSG) today announced the publication of an article in Future Oncology that has demonstrated in patients with metastatic Merkel cell carcinoma (mMCC), non-progression during treatment with the anti-PD-L1 immunotherapy avelumab correlates with gains in health-related quality of life (HRQoL).

"MCC is a potentially devastating disease with few therapeutic options for patients until recently. The approval of avelumab and targeting the PD-1/PD-L1 pathway for patients with MCC has provided an important new option, with some patients achieving durable responses with a tolerable safety profile," the authors explained.

In this study, the researchers utilized data from the JAVELIN Merkel 200 Phase II trial. By analyzing these data, the team was able to demonstrate that the reduction of tumor size experienced under treatment with avelumab correlated with improvements in patients' health status, as measured by both generic and skin cancer-specific HRQoL instruments.

"Now we have evidence that treatment with immunotherapy, such as avelumab, may be associated with an improvement in patient quality of life that also appears to be coordinated with lack of disease progression. Our study adds new insights into an important patient-reported outcome that further supports the significance of immunotherapy in patients with MCC," the authors stated.

"MCC is a very aggressive form of skin cancer; therefore, it is surprising that there is a lack of consensus on the most effective treatment strategy", commented Commissioning Editor for Future Oncology, Rachel Jenkins. "Following on from this, immunotherapy is a key area right now so it is exciting to see that avelumab has shown promise in delaying MCC progression and improving quality of life."

The full research article is available here: http://www.futuremedicine.com/doi/10.2217/fon-2017-0470

You can also access the full article plus related-exclusive content on Oncology Central: http://www.oncology-central.com/2017/12/08/nonprogression-avelumab-treatment-associated-gains-quality-life-metastatic-merkel-cell-carcinoma/
-end-
About Future Oncology

Future Oncology is a MEDLINE-indexed journal, with an impact factor of 2.131. The journal covers the latest scientific and clinical issues, together with the economic and policy issues of relevance to oncologists. The journal delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. http://www.futuremedicine.com/journal/fon

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.futuresciencegroup.com

Future Science Group

Related Skin Cancer Articles from Brightsurf:

Increasing the effectiveness of immunotherapy against skin cancer
Researchers at the University of Bern have discovered a mechanism in the body's own immune system which is responsible for the maturation and activation of immune cells.

New electronic skin can react to pain like human skin
New pain-sensing prototype mimics the body's near-instant feedback response and reacts to painful sensations with the same lighting speed that nerve signals travel to the brain.

Studying how skin cancer starts
New research by Ortiz-Rodríguez and mentor Carlos Crespo, a professor and lead researcher in the The Crespo Group lab, reveals for perhaps the first time how quickly certain pre-cancerous lesions can form on the DNA of our skin when exposed to sunlight.

Skin-to-skin 'kangaroo care' shows important benefits for premature babies
A world-first study led by Monash University has demonstrated significant benefits to a premature baby's heart and brain function when held by the parent in skin-to-skin contact.

Mother/infant skin-to-skin touch boosts baby's brain development and function
As the world prioritizes social distancing due to COVID-19, research shows that extended use of Kangaroo Care, a skin-to-skin, chest-to-chest method of caring for a baby, can positively benefit full-term infants and their mothers, with important implications for post-partum depression.

IU researcher makes skin cancer discovery
An Indiana University cancer researcher has identified eight new genomic regions that increase a person's risk for skin cancer.

Skin-to-skin contact do not improve interaction between mother and preterm infant
Following a premature birth it is important that the parents and the infant quickly establish a good relationship.

Research reveals potential dangers during skin-to-skin contact for mother and baby following cesarean section birth
Research in the latest edition of the European Journal of Anaesthesiology (the official journal of the European Society of Anaesthesiology) reports the potential dangers of allowing skin-to-skin contact for mother and baby in the operating room, following a cesarean section birth.

Helping skin cells differentiate could be key to treating common skin cancer
A new study from Penn researchers has identified the key regulator that controls how the skin replaces itself and which can determine if cells turn into cancer.

Protein linked to aggressive skin cancer
Almost 300,000 people worldwide develop malignant melanoma each year. The disease is the most serious form of skin cancer and the number of cases reported annually is increasing, making skin cancer one of Sweden's most common forms of cancer.

Read More: Skin Cancer News and Skin Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.